PRTC PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About PureTech Health (LON: PRTC)
›
PureTech Health (LON: PRTC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 90 employees.
The shares were at 116.00 GBp on 19 November 2026, down 2.5% over 52 weeks. Its 52-week range is 106.60 GBp to 143.60 GBp: the price is 19.2% below the high and 8.8% above the low.
Its market capitalisation is 282.37M GBP.
PureTech Health reports return on equity of -35.2% and revenue up 92.2% year over year.
It holds more cash than debt, a net cash position of 8.79M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 303.00 GBp is 161.2% above the current price. The next earnings report is expected on 29 April 2027.